Introduction
The root of Salvia miltiorrhiza Bunge (SMB), a well-known traditional Chinese herbal medicine, has been widely used in China to treat coronary heart disease, cerebrovascular disease, hepatitis, hepatocirrhosis and chronic renal failure [1] . Cryptotanshinone (CT) is the main active component of SMB and has attracted worldwide attention due to its pharmacological activities, including antibacterial [2] , anti-inflammatory [3] and anticancer activities [4, 5] . Recently, the pharmacokinetic characteristics of cryptotanshinone have been studied in animals. The oral bioavailability of cryptotanshinone in pigs was extremely poor because the plasma concentration was almost undetectable at a dose of 40 mg/kg [6] . Using HPLC-MS, the maximum plasma concentration (C max ) of cryptotanshinone was below 20 ng/mL after oral administration of total tanshinones (containing 12% of cryptotanshinone) to rats at a dose of 350 mg/kg [7] . Our recent studies showed that the C max of cryptotanshinone was below 20 ng/mL after oral administration of tanshinone capsules to healthy Chinese volunteers at a dose of 1000 mg (containing 88 mg cryptotanshinone) [8] . Although the poor oral availability of cryptotanshinone has been partly explained by P-glycoprotein (P-gp)-mediated efflux [9, 10] , cryptotanshinone might undergo extensive first-pass metabolism [11] . Song et al reported six phase I metabolites of cryptotanshinone in pigs [12] . Dai et al -totanshinone in both in vivo and in vitro experiments in rats [13] . Dehydrogenated and hydroxylated metabolites were the main phase I metabolites. Liu et al studied phase I and phase II metabolism both in vitro and in vivo for individual and mixed tanshinones in rats and found that oxidation and O-glucuronidation were the major pathways in phase I and phase II metabolism [14] . However, no information is available regarding Drug metabolism is classified into phase I and phase II -that contribute to phase I metabolism of drugs are often from the CYP1, 2 and 3 families and include CYP1A2, 2A6, 2C8, 2C9, 2C19, 2D6 and 3A4 [15] . Phase II metabolism (conjugation) often occurs in metabolites produced by phase I oxidation and in parent drugs bearing appropriate functional moieties, such as hydroxyl and carboxylic acid groups. UDP-glucuronosyltransferase (UGT)-mediated glucuronidation is responsible for the clearance of 35% of drugs [16] the UGT1A and 2B families are the main contributors to this been reported to contribute to the metabolism of over 80% of clinical drugs [17] drugs by both CYPs and UGTs in humans is of great value.
As we know, tanshinone IIA is a dehydrogenated metabolite of cryptotanshinone, and this metabolite has many pharmacological activities [18, 19] , although the other main metabolites of cryptotanshinone might also have unreported pharmacologifor predicting the pharmacokinetic properties of drug candidates and assessing the possibility of drug-drug interactions -totanshinone metabolites in human liver microsomes (HLMs) and contribution to the metabolism of cryptotanshinone by
Materials and methods

Chemicals
chased from National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). Furafylline, dimethyl sulfoxide (DMSO), NADPH, uridine diphosphoglucuronic -chased from Sigma-Aldrich (St Louis, MO, USA). Pooled HLMs (n=10), pooled human liver S9 fractions (S9) (n=10) and pooled cytosol (n=10) were purchased from the Rild Research Institute for Liver Diseases (Shanghai, China). HPLC-grade methanol and acetonitrile were purchased from Tedia Company (USA). Ammonium acetate and analytic grade formic acid were purchased from the China National Pharmaceutia Milli-Q system (Millipore Corporation, France). cDNA-CYP2C9, CYP2C19, CYP2D6, and CYP1A2) and cDNA-1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15 and 2B17) were purchased from BD Biosciences (Woburn, MA, USA).
Phase I metabolism assay microsomes -ture was preincubated at 37 °C for 5 min. The reaction was acetonitrile at predetermined time points. Control incubations were performed without NADPH.
Glucuronidation assay
2 to create pores and enhance the access of UGPGA and subThe incubation mixture was preincubated at 37 °C for 5 -of O-glucuronide, hydrolysis of the metabolite was performed
In all experiments, cryptotanshinone was dissolved in DMSO to obtain a 10 mmol/L stock solution and serially -age of organic solvent in the incubation system did not exceed 0.1%.
Chemical inhibition analysis in HLMs
none metabolism were evaluated using inhibition experiments.
used as the inhibitor for all of the UGTs because diclofenac sodium inhibits UGT1A9, 2B4 and 2B7 [20, 21] . Cryptotanshinone
The substrate and inhibitors were preincubated in the incubation mixture with HLMs at 37 °C for 5 min. NADPH (for CYPs, NADPH+UDPGA for UGTs) was then added to each reaction, and the reaction mixture was incubated for another -dine and diclofenac sodium were 1, 10, 10, 10, 10, 10, 5, and inhibitors was used as the control.
Assay with recombinant human CYP enzymes Incubation of each recombinant human CYP isoform was carried out as described in the microsomal study. Cryptotanshi--none and its metabolites were measured in reaction mixtures containing recombinant human CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4.
Glucuronidation assay with recombinant UGTs -phate (pH 7.4) were added to a 1.5 mL Eppendorf tube that had been preincubated at 37 °C for 5 min. The reaction was preincubated at 37 °C for 5 min, incubated in the mixture with ice-cold acetonitrile at predetermined time points. The soluwas added as the NQO1 donor [22] A panel of commercially available UGT isoforms, including UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B15, and -none glucuronidation. The reaction was initiated by incuba---mined time points (0 min and 40 min).
Chemical inhibition analysis in S9
Selective chemical inhibitors were used to investigate the phase I metabolites in S9. The selective inhibitors and concen- [21, 23] . Cryptotanshinone (2 30 min in the presence of chemical inhibitors under the abovedescribed conditions. Control incubations without the chemical inhibitors were also performed. The formation of m/z of
Sample preparation
The samples were vortexed and centrifuged at 12000 r/min for 10 min. The supernatant was collected and subjected to analysis by HPLC-MS/MS.
Sample analysis conditions
mass spectrometer was used to accurately determine the masses of the metabolites of cryptotanshinone. Simultaneous determination of the metabolic stability and metabolite identity was performed using QTRAP mass spectrometry.
Cryptotanshinone and its metabolites were investigated in various experiments by LC-MS/MS. An Agilent 1260 system (Agilent Technologies, Santa Clara, CA, USA) that included a and sample delivery. An Agilent Eclipse XDB-C18 instru- declustering potential was set at 104 eV, the collision energy was set at 33 eV, and the collision cell exit potential was set at 12 eV for analysis of all of the analytes. The other parameters 1 2 -sion-activated dissociation gas, 5 psi.
Authentic standards of the metabolites (except M1-3) were using the peak area. Low, medium and high contents of metabolites were produced in the microsomal incubation system by three different concentrations of cryptotanshinone.
determination of cryptotanshinone and its metabolites were and its metabolites was observed. For metabolite identification, accurate mass determination of the parent compound and its metabolites was performed on an Agilent 6530 QTOF mass spectrometer (Agilent, Santa Clara, CA, USA). The instrument -2 pressure (45 psi), sheath gas temperature (350 °C), mass scan fragment (150 eV), and collision energy (15 eV). Mass Hunter Workstation, a software package for the 6530 series QTOF, was the obtained data. The LC system and conditions were the same as above.
Data analysis
The data points represent the mean of duplicate estimates.
, where V represents the volume of the incubation system and P represents the microsomal protein of the incubation system. The relative contributions of each CYP to cryptotanshinone in human liver microsomes were determined using the fracfm). The fm value was determined from -tors in HLMs. The initial rate of disappearance (k) of cryptotanshinone in the presence (k with inh ) and absence of (k no inh ) of inhibitors was determined as described above. fm was calculated as described by Yang et al [24] .
Data are expressed as the mean±SD. Multiple comparisons were performed with one-way ANOVAs. P<0.05 was consid-
Results
Fifty-two proposed metabolites were detected by LC-MS/MS, -try, and Lightsight TM software using predictive MRM-IDA-EPI in HLMs in the presence of NADPH+UDPGA. There were 52 metabolites, including dehydrogenation, loss of water, oxidation, di-oxidation, demethylation, di-demethylation, and glucuronidation forms. Cryptotanshinone and its major phase I and phase II metabolites in human liver microsomes are presented in Table 1 . The product ions and retention times of cryptotanshinone as well as these main metabolites in HLMs using QTRAP and QTOF M1-1, M1-2 and M1-3 were eluted at 10.47, 11.20 and 12.61 min, respectively. Those metabolites had an ion [M+H] + at m/z of 295, which suggested that these metabolites might be the dehydrogenated metabolites of cryptotanshinone. The MS 2 spectra of protonated M1-1, M1-2 and M1-3 revealed that the main fragment ions were 2 Da less than those of cryptotanshinone (Table 1) . The MS 2 spectra of M1-3 were the same tanshinone IIA. According to the literature, M1-1 and M1-2 -drocryptotanshinone [25] . M2-1, M2-2 and M2-3 were eluted at 9.12, 9.31 and 10.47 min, respectively. These metabolites had an ion [M+H] + at m/z of 313, which is 16 Da heavier than that of cryptotanshinone.
+ ion at m/z of 295, formed by the loss of H 2 O, was observed in the MS/MS spectrum. The major product ions are shown in Table 1 . This information indicated that M2-1, M2-2 and M2-3 were metabolites of cryptotanshinone with one hydroxyl group.
M3-1, M3-2 and M3-3 were eluted at 11.12, 11.32 and 11.68 min, respectively. These metabolites had a protonated molecule [M+H] + at m/z of 473. The MS/MS spectrum of these metabolites showed an intense ion at m/z of 295 correspondfrom the chromatogram. This result indicated that M3-1, M3-2 and M3-3 were the glucuronide conjugate. The fragment ions of M3 at m/z of 295, 277 and 249 were similar to those of cryptotanshinone and were 2 Da heavier than those of dehydrocryptotanshinone. The product ion at m/z of 295 was proposed to be the hydrogenated product of dehydrocryptotanshinone, C-12 position. M3 was proposed to be the glucuronide conjugate of hydrogenated dehydrocryptotanshinone.
M4-1 and M4-2 were eluted at 8.21 and 8.58 min, respectively. Both of these metabolites had an [M+H] + ion at m/z of The product ion spectra of M4-1 and M4-2 were similar, which indicated that these metabolites might be isomers. Metabolic stability and the metabolic reactions of cryptotanshinone in HLMs were evaluated.
Based on the peak areas of the metabolites observed via -ments under the positive ion mode, eleven metabolites of cryptotanshinone were selected for multiple reaction monitor-
ing. MRM analysis of the metabolites of cryptotanshinone with mass transitions (m/z hydroxylated forms, respectively. Glucuronidation products were represented by mass transitions (m/z To determine the NADPH-and NADPH+UDPGA-dependent metabolic stability of cryptotanshinone, the disappearance of the parent compound was measured at six time points between 0 and 60 min in HLM in the presence of NADPH or NADPH+UDPGA. More than 50% of cryptotanshinone was eliminated within 20 min in the presence of NADPH+UDPGA, but comparable depletion occurred over more than 30 min in the presence of NADPH. The CL int (in vitro) values of cryptotanshinone were 1.61 and 2.38 mL·h -1 ·mg -1 in the presence of the CL int (liver) values of cryptotanshinone were 76.4 and 112.9 L/h in the presence of NADPH and NADPH+UDPGA, respectively. HLMs can generate some phase I and phase II metabolites of cryptotanshinone that are extensively metabo-
The eleven main metabolites of cryptotanshinone were selected to plot the peak area-time curves over a 60-min incubation in NADPH or NADPH+UDPGA (Figure 2) . The formation of M1-1, M1-2, M1-3, M2-1, M2-2, and M2-3 increased for over 1 h in HLMs with NADPH. The formation of the six phase I metabolites decreased after 10 to 30 min, whereas the M4-1, M4-2) increased for over 1 h in HLMs with NADPH and UDPGA, which indicated that phase I metabolites might be transformed into phase II metabolites by HLMs with NADPH and UDPGA. cryptotanshinone in human liver microsomes Selective inhibitors of the seven major CYPs were used to metabolism in HLMs. As shown in Figure 3 and Table 2 , NADPH in the control group. Inhibition (%) of cryptotanshinone metabolism in HLMs with NADPH and the inhibitors of CYP1A2, CYP2A6, CYP2C19 and CYP3A4 were 35.8%, 57.6%, 58.0% and 50.0%, respectively (P<0.05). These results suggested that CYP1A2, CYP2A6, CYP2C19 or CYP3A4 may be responsible for cryptotanshinone metabolism in HLMs. Furthermore, the fm values of the total cryptotanshinone metabolism by CYP2C19, CYP2A6, CYP3A4, and CYP1A2 were 25.9%, 25.7%, 22.3%, and 16.0%, respectively, as shown in Table 2 . By contrast, only marginal inhibition (<10%) was observed with either CYP2C8 or CYP2C9. Therefore, CYP2C19, CYP2A6, involved in the formation of phase I metabolites.
Assay with recombinant human CYPs -lism of cryptotanshinone, the catalytic activities of 7 individual recombinant human CYP isoforms (rCYP) were evaluated. As shown in Figure 4 , rCYP1A2, rCYP2A6, rCYP2C19 or rCYP3A4 may play a major role in cryptotanshinone metabolism.
As shown in Figure 4 , rCYP2C19 had the largest role in the formation of M1-1, M1-3 and M2-3, although rCYP1A2 was also involved in the formation of M1-1 and M2-3. The rCYP2A6 isoform showed the highest metabolic activity in reactions forming M2-2, although the rCYP3A4 isoform also showed potent metabolic activity in reactions forming CYP2C19, CYP2A6 and CYP3A4 in cryptotanshinone phase I metabolism. Moreover, rCYP2C8 and rCYP2D6 participated in cryptotanshinone phase I metabolism to some extent. cryptotanshinone Glucuronidation of cryptotanshinone by 12 commercially cryptotanshinone. The reduced catechol intermediate was not detected by LC-MS/MS after the supernatant was dried after cryptotanshinone incubation with NADPH. Thus, human liver cytosol was added as the NQO1 donor to produce reduced cryptotanshinone or its metabolites.
involved in the formation of M3-2 and M3-3 from reduced dehydrocryptotanshinone. As shown in Figure 4D , glucuroniby UGT2B7 with minor contributions from UGT2B4.
Given the lack of specific inhibitors for UGTs, diclofenac sodium has been shown to be a selective inhibitor of UGT1A9, 2B4, and 2B7 [22, 24] . Thus, the potential inhibitory effect of diclofenac sodium was investigated in cryptotanshinone glucuronidation. Inhibition (%) of cryptotanshinone metabolism was 50% in HLMs with NADPH and UDPGA in the presence UGT1A9, UGT2B4 and UGT2B7 were also important contributors to cryptotanshinone metabolism.
in S9
Selective chemical inhibitors were used to investigate the and its phase I metabolites in S9. Dicumarol and chlorpromafound that the formation of m/z of 473 metabolites was effectively inhibited (up to 94%) by dicumarol (a NQO1 inhibitor) in the presence of NADPH in S9. By contrast, no inhibition NQO1 is mainly distributed in the cytosol, this study used human liver cytosol as the NQO1 donor to produce reduced cryptotanshinone, which was then subjected to glucuronidation screening with a panel of 12 commercially available isoforms of rUGT.
On the basis of the present work, the 11 main metabolites of liver microsomes. A possible metabolic pathway of cryptotanshinone in human liver microsomes was proposed, as shown in Figure 5 . The six phase I metabolites were formed from two or hydroxylations were the hydrogenated products of dehydrocryptotanshinone M3-1, M3-2, and M3-3. These results suggested that cryptotanshinone underwent -
Discussion
In this study, the metabolic characteristics of cryptotanshinone metabolites, including loss of water, oxidation, di-oxidation, demethylation, di-demethylation furan ring cleavage metabolites, and five glucuronide conjugation phase II metabolites. We found that cryptotanshinone underwent extensive phase I and phase II metabolism in HLMs. Based on the metabolite the two main metabolic routes, which involved six phase I M2-3). M1-1, M1-2, and M1-3 were dehydrogenated metabolites, whereas M2-1, M2-2, and M2-3 were hydroxylated that incubated cryptotanshinone and NADPH in rat and pig liver microsomes [11, 12] . After adding UDPGA to the incubation system, another five main phase II metabolites (M3-1, M3-2, -gates. When cryptotanshinone was incubated in HLMs with UDPGA, no glucuronidation of cryptotanshinone was found, so cryptotanshinone cannot directly conjugate with glucuronic acid without a hydroxyl group, as opposed to tanshinone IIA [17] .
metabolic stability, can play a critical role in the safe use of drugs in clinical medicine. When lacking authentic metabolite -toring the disappearance of the parent compound over time in an in vitro system to determine the intrinsic clearance (CL int ). In HLMs, the CL int (in vitro) of cryptotanshinone was 1.61 and 2.38 mL·h -1 ·mg -1 in the presence of NADPH and NADPH+UDPGA, respectively. Using the IVIVE method, the CL int in the human liver was 76.4 or 112.9 L/h, which suggested that crypto- [26] . In this study, metabolism of cryptotanshinone in the presence of NADPH and UDPGA better reflected cryptotanshinone metabolism in vivo abundantly in the gastrointestinal tract and liver, was the main metabolites from cryptotanshinone. Therefore, cryptotanshinone probably suffered intensive metabolism in the liver and intestinal tract mediated by CYPs and UGTs, which resulted in the low bioavailability of cryptotanshinone. The involvement of CYP isoforms in cryptotanshinone metabolism was studied by chemical inhibition in HLM S and using recombinant human CYPs. CYP2C19, CYP2A6, CYP3A4, and CYP1A2 inhibited cryptotanshinone metabolism by 58.0%, 57.6%, 50.0%, and 35.8%, respectively. The fm values of CYP2C19, CYP2A6, CYP3A4, and CYP1A2 in HLMs were 25.9%, 25.7%, were the major contributors to cryptotanshinone metabolism. CYP2C19, CYP1A2 and CYP3A4 were responsible for dehydrogenation, whereas CYP2A6, CYP3A4, and CYP2C19 were responsible for hydroxylation. Liu et al [27] found that CYP2A6 -shinone IIA in human liver microsomes. In the present study, we found that the hydroxyl metabolite (M2-3) was also formed by CYP2A6, although a topic for future research is whether the -tion metabolites of cryptotanshinone were reported as being dehydroxylated metabolites of cryptotanshinone were mainly The phase II metabolite observed for the [M+H] + ion at 473 (dicumarol), whereas no inhibition was observed with AOX et al [22] reported that NQO1 catechol intermediate followed by an immediate glucuronidation and that this pathway was the predominant metabolic The metabolite at m/z of 475 was found by Q1 scanning with QTOF of the incubation samples, but the peak area was less than that of the metabolite at m/z of 473 (data not shown). Although NQO1 is mainly distributed in the cytosol [20] , there is a small amount in human liver microsomes. In the present study, the peak area of the metabolite at m/z of 473 was higher than that of the metabolite at m/z of 489 in HLMs. Because than in HLMs, there is much more of the metabolite at m/z of 473 in the human body. This result suggested that NQO1-major phase II metabolic pathway for cryptotanshinone.
Glucuronidation of hydroxylated metabolites was primar-2B4. Lacking UGT2B4 and UGT2B7 expression in the intestinal tract, the metabolite at m/z of 489 was possibly metabofollowed by hydroxylation of CYP.
were CYP2C19, CYP1A2, CYP2A6, CYP3A4, UGT1A9 and UGT2B7. Genetic variations of CYP2C19, CYP2A6, CYP1A2, CYP3A4, UGT1A9, UGT2B7 and CYP3A4 have been reported in humans, and the polymorphic nature of CYPs and UGTs could affect individual drug exposure to a great extent [28] [29] [30] [31] [32] [33] . Therefore, potential individual differences in pharmacological responses to cryptotanshinone might occur due to differential metabolic capacity. CYP2A6, CYP3A4, UGT1A9 and UGT2B7. We found that cryptotanshinone induced CYP3A4 and P-gp activity in human liver hepatocytes [8] . Yu reported that cryptotanshinone induced expression of CYP2C19, UGT1A9 and UGT2B7, which are the target genes of PXR [34] . Zhang reported that cryptotanshinone also induced CYP1A2 [35] . Long-term administration of cryptotanshinone induced CYP2C19, CYP1A2, CYP3A4, UGT1A9 and UGT2B7 to enhance cryptotanshinone metabolism in the liver. The exposure of the human body to crypto- tanshinone would be reduced, possibly leading to tolerance of cryptotanshinone.
--NADPH-supplemented HLM generated six main dehydrogenation and hydroxylation metabolites from cryptotanshinone, and UDPGA-supplemented liver microsomes generated five main phase II glucuronidation metabolites. This study shows major contributors to the transformation of cryptotanshinone hydroxylation metabolites and that CYP2C19, CYP1A2 and CYP3A4 are the major contributors to the transformation of its hydrogenation metabolites in human liver microsomes. This study also shows that the metabolite at m/z of 473 was mediated by UGT1A9 and the metabolite at m/z of 489 was mediated by UGT2B7 and UGT2B4. Elucidation of the CT to understand CT metabolism but also to predict likely drug interactions of Western medicines that are used concomitantly in clinical treatment.
